Michael Barbella, Managing Editor01.27.21
Kwivik Therapeutics Inc. and EirMed are joining forces on product commerialization. The two firms are working together to market some of Kwivik's therapeutic devices.
"We are excited to be working with EirMed as we enter a growth phase in our business," said Julian Ross, CEO of Kwivik Therapeutics. "EirMed is a fine organization and will significantly expand our capacity and depth with their infrastructure, design, engineering, manufacturing, quality control, and regulatory compliance capabilities."
Kwivik is a medtech developer of disruptive technologies for respiratory and emergency medical markets. The company has developed a pipeline of products for certain respiratory, emergency medical, asthma, migraine/cluster headache, wound care and skin care markets, with a combined market size exceeding a remarkable $750 billion. These products are tracked, monitored and enhanced with Kwivik's proprietary, cloud-based Mobile, IoT and AI technologies, with the goal of improving medical outcomes and saving lives – more efficiently and effectively than ever before.
EirMed, based in Menomonie, Wis., manufactures custom designed and engineered medical devices. With an array of capabilities, EirMed designs, engineers, manufactures, assembles, and packages advanced medical devices for markets such as respiratory, home healthcare, emergency, and disposables. EirMed is ISO 13485 certified and has more than 50,000 square feet of clean room, manufacturing and warehouse space. EirMed will be responsible for a significant number of Kwivik's custom molded components as well as various secondary processes.
"We are pleased to be partnering with Kwivik and to contribute to the proliferation of Kwivik's lifesaving products," stated Rick Curtis, president of EirMed. "As a trusted accelerator of medical device commercialization we look forward to working with Kwivik and its teams to exceed their business plan goals," he added.
Kwivik has invested in and developed all of its own tooling located at EirMed.
"We are excited to be working with EirMed as we enter a growth phase in our business," said Julian Ross, CEO of Kwivik Therapeutics. "EirMed is a fine organization and will significantly expand our capacity and depth with their infrastructure, design, engineering, manufacturing, quality control, and regulatory compliance capabilities."
Kwivik is a medtech developer of disruptive technologies for respiratory and emergency medical markets. The company has developed a pipeline of products for certain respiratory, emergency medical, asthma, migraine/cluster headache, wound care and skin care markets, with a combined market size exceeding a remarkable $750 billion. These products are tracked, monitored and enhanced with Kwivik's proprietary, cloud-based Mobile, IoT and AI technologies, with the goal of improving medical outcomes and saving lives – more efficiently and effectively than ever before.
EirMed, based in Menomonie, Wis., manufactures custom designed and engineered medical devices. With an array of capabilities, EirMed designs, engineers, manufactures, assembles, and packages advanced medical devices for markets such as respiratory, home healthcare, emergency, and disposables. EirMed is ISO 13485 certified and has more than 50,000 square feet of clean room, manufacturing and warehouse space. EirMed will be responsible for a significant number of Kwivik's custom molded components as well as various secondary processes.
"We are pleased to be partnering with Kwivik and to contribute to the proliferation of Kwivik's lifesaving products," stated Rick Curtis, president of EirMed. "As a trusted accelerator of medical device commercialization we look forward to working with Kwivik and its teams to exceed their business plan goals," he added.
Kwivik has invested in and developed all of its own tooling located at EirMed.